TM4SF1-cMET bispecific antibody drug conjugate (Tavotek Biotherapeutics)

N/A

Report date: 2025/06/30 16:48:03

Base Information

Drug NameTM4SF1-cMET bispecific antibody drug conjugate (Tavotek Biotherapeutics)
Drug Alias NameBispecific TM4SF1-cMET MMAE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload
Mechanisms of ActionAnti-Transmembrane 4 L6 family member 1Anti-Hepatocyte growth factor receptorTubulin polymerisation inhibitors
TargetsTransmembrane 4 L6 family member 1Hepatocyte growth factor receptorTubulin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTavotek Biotherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesTavotek Biotherapeutics
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A